Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Satoshi Ichikawa

Showing results (201-210 of 241) with videos related to

Pageof 25
Sort By:
Cancer Science|March 1, 2019
Phase I study of tirabrutinib (ONO-4059/GS-4059) in patients with relapsed or refractory B-cell malignancies in JapanWataru Munakata, Kiyoshi Ando, Kiyohiko Hatake, et al.
Leukemia & Lymphoma|July 2, 2024
Safety and efficacy of acalabrutinib and obinutuzumab in treatment-naive chronic lymphocytic leukemia: a Japanese phase 1 studyJun Takizawa, Takanori Teshima, Daisuke Ennishi, et al.
Journal of the American Chemical Society|December 18, 2003
Fundamental role of the fostriecin unsaturated lactone and implications for selective protein phosphatase inhibitionSuzanne B Buck, Christophe Hardouin, Satoshi Ichikawa, et al.
Experimental Hematology & Oncology|August 7, 2013
Clinicopathological analysis of primary adrenal diffuse large B-cell lymphoma: effectiveness of rituximab-containing chemotherapy including central nervous system prophylaxisSatoshi Ichikawa, Noriko Fukuhara, Ai Inoue, et al.
Chemotherapy|May 21, 2026
Clinical Feasibility of Platinum-Based Chemotherapy Followed by Avelumab Maintenance after Enfortumab Vedotin plus Pembrolizumab in Metastatic Urothelial Carcinoma: A case seriesMasaomi Ikeda, Satoshi Ichikawa, Shunsuke Ito, et al.
Internal Medicine (Tokyo, Japan)|March 13, 2018
Successful Cord Blood Stem Cell Transplantation for Primary Cutaneous CD8-positive Aggressive Epidermotropic Cytotoxic T-cell Lymphoma Complicated with Cerebral InfiltrationSatoshi Ichikawa, Noriko Fukuhara, Shunsuke Hatta, et al.
Cancer Science|January 24, 2014
Association between BACH2 expression and clinical prognosis in diffuse large B-cell lymphomaSatoshi Ichikawa, Noriko Fukuhara, Hiroki Katsushima, et al.
Antibiotics (Basel, Switzerland)|May 24, 2024
The MraY Inhibitor Muraymycin D2 and Its Derivatives Induce Enlarged Cells in Obligate Intracellular <i>Chlamydia</i> and <i>Wolbachia</i> and Break the Persistence Phenotype in <i>Chlamydia</i>Iris Löckener, Lara Vanessa Behrmann, Jula Reuter, et al.
Stem Cells (Dayton, Ohio)|April 20, 2016
Chemical Screening Identifies EUrd as a Novel Inhibitor Against Temozolomide-Resistant Glioblastoma-Initiating CellsYoshihiro Tsukamoto, Naoki Ohtsu, Smile Echizenya, et al.
Scientific Reports|August 26, 2022
Exploring the mechanistic link between SF3B1 mutation and ring sideroblast formation in myelodysplastic syndromeTetsuro Ochi, Tohru Fujiwara, Koya Ono, et al.
Pageof 25

Showing results (201-210 of 241) with videos related to

Sort By:
Pageof 25
Cancer Science|March 1, 2019
Phase I study of tirabrutinib (ONO-4059/GS-4059) in patients with relapsed or refractory B-cell malignancies in JapanWataru Munakata, Kiyoshi Ando, Kiyohiko Hatake, et al.
Leukemia & Lymphoma|July 2, 2024
Safety and efficacy of acalabrutinib and obinutuzumab in treatment-naive chronic lymphocytic leukemia: a Japanese phase 1 studyJun Takizawa, Takanori Teshima, Daisuke Ennishi, et al.
Journal of the American Chemical Society|December 18, 2003
Fundamental role of the fostriecin unsaturated lactone and implications for selective protein phosphatase inhibitionSuzanne B Buck, Christophe Hardouin, Satoshi Ichikawa, et al.
Experimental Hematology & Oncology|August 7, 2013
Clinicopathological analysis of primary adrenal diffuse large B-cell lymphoma: effectiveness of rituximab-containing chemotherapy including central nervous system prophylaxisSatoshi Ichikawa, Noriko Fukuhara, Ai Inoue, et al.
Chemotherapy|May 21, 2026
Clinical Feasibility of Platinum-Based Chemotherapy Followed by Avelumab Maintenance after Enfortumab Vedotin plus Pembrolizumab in Metastatic Urothelial Carcinoma: A case seriesMasaomi Ikeda, Satoshi Ichikawa, Shunsuke Ito, et al.
Internal Medicine (Tokyo, Japan)|March 13, 2018
Successful Cord Blood Stem Cell Transplantation for Primary Cutaneous CD8-positive Aggressive Epidermotropic Cytotoxic T-cell Lymphoma Complicated with Cerebral InfiltrationSatoshi Ichikawa, Noriko Fukuhara, Shunsuke Hatta, et al.
Cancer Science|January 24, 2014
Association between BACH2 expression and clinical prognosis in diffuse large B-cell lymphomaSatoshi Ichikawa, Noriko Fukuhara, Hiroki Katsushima, et al.
Antibiotics (Basel, Switzerland)|May 24, 2024
The MraY Inhibitor Muraymycin D2 and Its Derivatives Induce Enlarged Cells in Obligate Intracellular <i>Chlamydia</i> and <i>Wolbachia</i> and Break the Persistence Phenotype in <i>Chlamydia</i>Iris Löckener, Lara Vanessa Behrmann, Jula Reuter, et al.
Stem Cells (Dayton, Ohio)|April 20, 2016
Chemical Screening Identifies EUrd as a Novel Inhibitor Against Temozolomide-Resistant Glioblastoma-Initiating CellsYoshihiro Tsukamoto, Naoki Ohtsu, Smile Echizenya, et al.
Scientific Reports|August 26, 2022
Exploring the mechanistic link between SF3B1 mutation and ring sideroblast formation in myelodysplastic syndromeTetsuro Ochi, Tohru Fujiwara, Koya Ono, et al.
Pageof 25